Outlook Therapeutics is trading 10.2% down at $0.93 on profit-taking and consolidation following a multi-day rally driven by recent FDA approval news.
- The stock is pulling back after sharp gains of 10.6% on July 29 and 4.0% on July 30 as short-term traders lock in profits.
- Broader weakness across the biotechnology sector is adding further downward pressure to the share price.